Laboratório de Patologia Clínica e de Anatomia Patológica, Hospital Israelita Albert Einstein, Sao Paulo, Brazil.
Department of Pathology, LIM01, Universidade de São Paulo Faculdade de Medicina, Sao Paulo, Brazil.
BMJ Open. 2021 Jul 9;11(7):e045852. doi: 10.1136/bmjopen-2020-045852.
Acute viral hepatitis is a disease of great clinical importance. This study proposes actions to better characterise cases of acute hepatitis in Brazil and to provide relevant information to institutionalised health policies within the Unified Health System. Available data on acute hepatitis in Brazil need to be re-evaluated regarding the different hepatotropic agent (hepatitis A to E virus) frequencies, as well as other agents that can cause similar clinical conditions, such as Herpes Simplex Virus 1 and 2(HSV1, HSV2), Varicella Zoster Virus (VZV), Cytomegalovirus (CMV), Epstein Barr Virus (EBV), Human Herpes Virus 6 and 7 (HHV6, HHV7), arbovirus (yellow fever, dengue, chikungunya, Zika), parvovirus B19, adenovirus, parechovirus, enterovirus, HIV, leptospirosis, toxoplasmosis and syphilis, in addition to autoimmune hepatitis. In this context, the primary aim of this study is the clinical-epidemiological and molecular characterisation of acute viral hepatitis in Brazilian health services from all geographical regions of the country. The present article describes the study protocol.
This study will evaluate 2280 patients with symptoms and/or signs suggestive of acute liver disease in Brazilian health institutions in all five geographic Brazilian regions. Demographic, epidemiological and clinical data will be collected, as well as blood samples to be analysed at Hospital Israelita Albert Einstein Clinical Laboratory.
Ethics approval was obtained at the national research ethics committee (Conselho Nacional de Ética em Pesquisa- CONEP-CAAE 00952818.4.1001.0071) and at all participating sites. Results will be published in journals and presented at scientific meetings.
急性病毒性肝炎是一种具有重要临床意义的疾病。本研究提出了一些行动方案,以更好地描述巴西急性肝炎病例,并为统一卫生系统内的机构卫生政策提供相关信息。巴西急性肝炎的现有数据需要重新评估不同嗜肝病毒(甲型至戊型肝炎病毒)的频率,以及其他可能引起类似临床病症的病原体,如单纯疱疹病毒 1 和 2(HSV1、HSV2)、水痘带状疱疹病毒(VZV)、巨细胞病毒(CMV)、EB 病毒(EBV)、人类疱疹病毒 6 和 7(HHV6、HHV7)、虫媒病毒(黄热病、登革热、基孔肯雅热、寨卡病毒)、细小病毒 B19、腺病毒、肠道病毒、人类免疫缺陷病毒、钩端螺旋体病、弓形虫病和梅毒,以及自身免疫性肝炎。在这种情况下,本研究的主要目标是对来自巴西全国各地卫生服务机构的急性病毒性肝炎进行临床流行病学和分子特征分析。本文描述了研究方案。
本研究将评估来自巴西各地卫生机构的 2280 例具有急性肝病症状和/或体征的患者。将收集人口统计学、流行病学和临床数据,以及血液样本,以便在以色列Albert Einstein 临床实验室进行分析。
国家研究伦理委员会(CONEP-CAAE 00952818.4.1001.0071)和所有参与地点均已批准伦理。结果将发表在期刊上,并在科学会议上展示。